AGIO (Agios Pharmaceuticals) חוב לטווח קצר להון

Agios Pharmaceuticals brings together dedicated researchers striving to combat hereditary pathologies. The specific nature of the therapy makes the business resilient to economic fluctuations, as the need for treatment remains constant. Serving as the primary valuation tool, this price chart on GURU.Markets recorded the indicator 0.02. The company is currently updating its blood medication portfolio, leveraging stable revenue from existing sales.

This ratio reflects the share of short-term liabilities within the equity structure, allowing for an assessment of current creditor pressure and liquidity risk. By analyzing the short-term leverage indicator, an investor can see how Agios Pharmaceuticals (AGIO) finances costly R&D processes to eventually convert drug development expenditures into high-margin global sales through patent protection.